Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
Authors:
Open Access
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 12 (12) , 3217-3230
Abstract
Introduction A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) and basal insulin plus liraglutide (BI plus Lira). Methods The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. Initial clinical data for iGlarLixi were based on the randomized, controlled LixiLan-L trial and the relative treatment effects for comparators were based on an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived from publicly available sources. Lifetime costs (in British Pound Sterling [£]) and quality-adjusted life-years (QALYs) were predicted; net monetary benefit (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay threshold of £20,000. Extensive scenario and sensitivity analyses were conducted. Results Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467). Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira). Conclusion In patients with T2DM with suboptimal glycemic control on basal insulin, iGlarLixi provides very similar outcomes and substantial cost savings, compared with other fixed and free combinations of insulins plus glucagon-like peptide-1 receptor agonists.Keywords
Funding Information
- Sanofi
This publication has 37 references indexed in Scilit:
- Review of Utility Values for Economic Modeling in Type 2 DiabetesValue in Health, 2014
- Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countriesQuality of Life Research, 2014
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal InsulinDiabetes Care, 2013
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Diabetologia, 2013
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trialThe Lancet, 2008
- Diagnosed diabetic retinopathy in France, Italy, Spain, and the United KingdomPrimary Care Diabetes, 2007
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- Guidelines for Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2004
- The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-makingCurrent Medical Research and Opinion, 2004